Pancreatic cancer overall, and aggressive ovarian cancers in particular, harbor aberrant KRAS signaling correlating with more metastatic and progressive disease and poorer response to chemotherapies [6,17,63,64,65]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.